Guillain-Barré syndrome: An update

Journal of Clinical Neuroscience

Volumn 16, Issue 6, 2009, Pages 733-741

  Vucic, Steve ^a,b   Kiernan, Matthew C ^a   Cornblath, David R ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute inflammatory demyelinating polyradiculoneuropathy; Acute motor and sensory axonal neuropathy; Acute motor axonal neuropathy; Guillain Barr syndrome

Indexed keywords

CORTICOSTEROID DERIVATIVE; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; HEPARIN; HEPATITIS VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; METHYLPREDNISOLONE; PLACEBO; SODIUM CHANNEL; STEROID; VOLTAGE GATED SODIUM CHANNEL;

ACUTE MOTOR AND SENSORY AXONAL NEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; AGE DISTRIBUTION; BLOOD PRESSURE MONITORING; CAMPYLOBACTER ENTERITIS; CEREBROSPINAL FLUID ANALYSIS; CHINA; CLINICAL FEATURE; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DEMYELINATION; DIFFERENTIAL DIAGNOSIS; DRUG TREATMENT FAILURE; ELECTROMYOGRAPHY; GUILLAIN BARRE SYNDROME; HEAD INJURY; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MORBIDITY; MOTOR NERVE CONDUCTION; MOTOR NEUROPATHY; NERVE CONDUCTION; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PERIPHERAL NERVE INJURY; PHYSIOTHERAPY; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PULSE RATE; REVIEW; SEX DIFFERENCE; SPINAL CORD INJURY; THROMBOSIS PREVENTION; TREATMENT DURATION;

AUTOANTIBODIES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOTHERAPY; INFECTION; NERVE FIBERS, MYELINATED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM; RANVIER'S NODES; SODIUM CHANNELS;

EID: 67349199109     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.08.033     Document Type: Review

References (163)

1. Guillain G., Barré J., and Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellilaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Med Hop Paris (1916) 1462-1470
2. Prineas J.W. Acute idiopathic polyneuritis. An electron microscope study. Lab Invest 26 (1972) 133-147
3. McKhann G.M., Cornblath D.R., Ho T., et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 338 (1991) 593-597
4. McKhann G.M., Cornblath D.R., Griffin J.W., et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33 (1993) 333-342
5. Griffin J.W., Li C.Y., Ho T.W., et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 39 (1996) 17-28
6. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 (1956) 57-65
7. Hughes R.A., and Cornblath D.R. Guillain-Barré syndrome. Lancet 366 (2005) 1653-1666
8. Hughes R.A., and Rees J.H. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 176 Suppl 2 (1997) S92-S98
9. Bogliun G., and Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 110 (2004) 100-106
10. Cheng Q., Wang D.S., Jiang G.X., et al. Distinct pattern of age-specific incidence of Guillain-Barré syndrome in Harbin, China. J Neurol 249 (2002) 25-32
11. Guillain-Barré Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Guillain-Barré Syndrome Study Group. Neurol Sci 2000;21:229-234.
12. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management. Drugs 64 (2004) 597-610
13. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 110 (1979) 105-123
14. Centers for Disease Control and Prevention. Guillain-Barré syndrome - United States. MMWR Morb Mortal Wkly Rep 1976;25:401-2.
15. Langmuir A.D., Bregman D.J., Kurland L.T., et al. An epidemiologic and clinical evaluation of Guillain-Barré Syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 119 (1984) 841-879
16. Breman J.G., and Hayner N.S. Guillain-Barré syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977. Am J Epidemiol 119 (1984) 880-889
17. Marks J.S., and Halpin T.J. Guillain-Barré Syndrome in recipients of A/New Jersey influenza vaccine. JAMA 243 (1980) 2490-2494
18. Hurwitz E.S., Schonberger L.B., Nelson D.B., et al. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 304 (1981) 1557-1561
19. Kaplan J.E., Katona P., Hurwitz E.S., et al. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination. JAMA 248 (1982) 698-700
20. Roscelli J.D., Bass J.W., and Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988. Am J Epidemiol 133 (1991) 952-955
21. Haber P., DeStefano F., Angulo F.J., et al. Guillain-Barré syndrome following influenza vaccination. JAMA 292 (2004) 2478-2481
22. Hughes R.A., Charlton J., Latinovic R., et al. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 166 (2006) 1301-1304
23. Lasky T., Terracciano G.J., Magder L., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 339 (1998) 1797-1802
24. Juurlink D.N., Stukel T.A., Kwong J., et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 166 (2006) 2217-2221
25. Souayah N., Nasar A., Suri M.F., et al. Guillain-Barré syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 25 (2007) 5253-5255
26. Centers for Disease Control and Prevention (CDC). Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005;54:1023-1025.
27. Lin T.M., Lee S.S., Lin R.T., et al. Guillain-Barré syndrome following facial bone fracture. J Plast Reconstr Aesthet Surg 59 (2006) 543-546
28. Duncan R., and Kennedy P.G. Guillain-Barré syndrome following acute head trauma. Postgrad Med J 63 (1987) 479-480
29. De Freitas G.R., De Freitas M.R., and Ferreira M.C. Guillain-Barré syndrome and head trauma. Case report. Arq Neuropsiquiatr 55 (1997) 315-318
30. Shuert G.T., and Gamble J.W. Guillain-Barré syndrome after mandibular surgery: report of case. J Oral Surg 30 (1972) 913-915
31. Hickory J.E., and Wilcox J.W. Cardiorespiratory arrest as a complication of Guillain-Barré syndrome in a postsurgical patient. J Oral Surg 36 (1978) 549-550
32. Renlund D.G., Hanley D.F., and Traill T.A. Guillain-Barré syndrome following coronary artery bypass surgery. Am Heart J 113 (1987) 844-845
33. Hogan J.C., Briggs T.P., and Oldershaw P.J. Guillain-Barré syndrome following cardiopulmonary bypass. Int J Cardiol 35 (1992) 427-428
34. Baldwin R.T., Pierce R.R., and Frazier O.H. Guillain-Barré syndrome after heart transplantation. J Heart Lung Transplant 11 (1992) 817-819
35. Parobeck V., Burnham S., and Laukhuf G.A. An unusual nursing challenge: Guillain-Barré syndrome following cranial surgery. J Neurosci Nurs 24 (1992) 251-255
36. Chouillard E., and Fingerhut A. Guillain-Barré syndrome following oesophagectomy. ANZ J Surg 74 (2004) 915-916
37. Foubert-Samier A., Penchet G., Yekhlef F., et al. Guillain-Barré syndrome secondary to cranial surgery: direct or fortuitous relationship?. Neurochirurgie 51 (2005) 604-606
38. Quattrocchi K.B., Miller C.H., Wagner Jr. F.C., et al. Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors. J Neurosurg 77 (1992) 694-699
39. Herbert T.B., and Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med 55 (1993) 364-379
40. Cohen S., Janicki-Deverts D., and Miller G.E. Psychological stress and disease. JAMA 298 (2007) 1685-1687
41. Hayes K.C., Hull T.C., Delaney G.A., et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 19 (2002) 753-761
42. Cosi V., and Versino M. Guillain-Barré syndrome. Neurol Sci 27 Suppl 1 (2006) S47-S51
43. Taly A.B., Gupta S.K., Anisya V., et al. Recurrent Guillain-Barré Syndrome: a clinical, electrophysiological and morphological study. J Assoc Physicians India 43 (1995) 249-252
44. Hiraga A., Mori M., Ogawara K., et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 76 (2005) 719-722
45. Chowdhury D., and Arora A. Axonal Guillain-Barré syndrome: a critical review. Acta Neurol Scand 103 (2001) 267-277
46. Reddel S.W., Barnett M.H., Yan W.X., et al. Chronic ophthalmoplegia with anti-GQ1b antibody. Neurology 54 (2000) 1000-1002
47. Lo Y.L. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve 36 (2007) 615-627
48. Mori M., Kuwabara S., Fukutake T., et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 56 (2001) 1104-1106
49. Blau I., Casson I., Lieberman A., et al. The not-so-benign Miller Fisher syndrome: a variant of the Guillain-Barré syndrome. Arch Neurol 37 (1980) 384-385
50. Matsumoto H., Kobayashi O., Tamura K., et al. Miller Fisher syndrome with transient coma: comparison with Bickerstaff brainstem encephalitis. Brain Dev 24 (2002) 98-101
51. Oomura M., Yamawaki T., Oe H., et al. Association of cardiomyopathy caused by autonomic nervous system impairment with the Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 74 (2003) 689-690
52. Odaka M., Yuki N., and Hirata K. Bilateral ballism in a patient with overlapping Fisher's and Guillain-Barré syndromes. J Neurol Neurosurg Psychiatry 67 (1999) 206-208
53. Asbury A.K., and Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 Suppl (1990) S21-S24
54. Hadden R.D., Cornblath D.R., Hughes R.A., et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 44 (1998) 780-788
55. Ho T.W., Mishu B., Li C.Y., et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 (1995) 597-605
56. Van der Meche F.G., Van Doorn P.A., Meulstee J., et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 45 (2001) 133-139
57. Van den Bergh P.Y., and Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 29 (2004) 565-574
58. Alam T.A., Chaudhry V., and Cornblath D.R. Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria. Muscle Nerve 21 (1998) 1275-1279
59. Cornblath D.R. Electrophysiology in Guillain-Barré syndrome. Ann Neurol (1990) S17-S20
60. Albers J.W., and Kelly Jr. J.J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 12 (1989) 435-451
61. McLeod J.G. Electrophysiological studies in the Guillain-Barré syndrome. Ann Neurol 9 (1981) 20-27
62. Albers J.W., Donofrio P.D., and McGonagle T.K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 8 (1985) 528-539
63. Vucic S., Cairns K.D., Black K.R., et al. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 115 (2004) 2329-2335
64. Gordon P.H., and Wilbourn A.J. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 58 (2001) 913-917
65. Ropper A.H., Wijdicks E.F., and Shahani B.T. Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barré syndrome. Arch Neurol 47 (1990) 881-887
66. Asbury A.K., Arnason B.G., and Adams R.D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 48 (1969) 173-215
67. Prineas J.W. Pathology of the Guillain-Barré syndrome. Ann Neurol 9 Suppl (1981) 6-19
68. Pritchard J., Makowska A., Gregson N.A., et al. Reduced circulating CD4+CD25+ cell populations in Guillain-Barré syndrome. J Neuroimmunol 183 (2007) 232-238
69. Hafer-Macko C.E., Sheikh K.A., Li C.Y., et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39 (1996) 625-635
70. Griffin J.W., Li C.Y., Macko C., et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 25 (1996) 33-51
71. Kuwabara S., Bostock H., Ogawara K., et al. The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve 28 (2003) 683-689
72. Hughes R., and Shirazi-Khalili A. Immune mechanisms in demyelinating polyradiculoneuropathies. In: Cros D. (Ed). Peripheral Neuropathy. A Practical Approach to Diagnosis and Management (2001), Lippincott Williams and Wilkins, Philadelphia 121-137
73. Press R., Mata S., Lolli F., et al. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome. J Neurol Sci 190 (2001) 41-47
74. Ho T.W., Willison H.J., Nachamkin I., et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 45 (1999) 168-173
75. Ogawara K., Kuwabara S., Mori M., et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48 (2000) 624-631
76. Rees J.H., Gregson N.A., and Hughes R.A. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 38 (1995) 809-816
77. Gregson N.A., Koblar S., and Hughes R.A. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med 86 (1993) 111-117
78. Weber F., Rudel R., Aulkemeyer P., et al. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels. Muscle Nerve. 23 (2000) 1414-1420
79. Takigawa T., Yasuda H., Kikkawa R., et al. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 37 (1995) 436-442
80. Arasaki K., Kusunoki S., Kudo N., et al. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 16 (1993) 587-593
81. Santoro M., Uncini A., Corbo M., et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 31 (1992) 385-390
82. Brismar T. Electrical properties of isolated demyelinated rat nerve fibres. Acta Physiol Scand 113 (1981) 161-166
83. Chiu S.Y., Ritchie J.M., Rogart R.B., et al. A quantitative description of membrane currents in rabbit myelinated nerve. J Physiol (Lond) 292 (1979) 149-166
84. Schwarz J.R., Reid G., and Bostock H. Action potentials and membrane currents in the human node of Ranvier. Pflugers Arch 430 (1995) 283-292
85. Catterall W.A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26 (2000) 13-25
86. Catterall W.A., Goldin A.L., and Waxman S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 (2005) 397-409
87. Waxman S.G., and Ritchie J.M. Molecular dissection of the myelinated axon. Ann Neurol 33 (1993) 121-136
88. Hille B. Ionic Channels of Excitable Membranes (1992), Sinauer Associates, Sunderland
89. Burke D., Kiernan M.C., and Bostock H. Excitability of human axons. Clin Neurophysiol 112 (2001) 1575-1585
90. Waxman S.G. Sodium channel blockade by antibodies: a new mechanism of neurological disease?. Ann Neurol 37 (1995) 421-423
91. Yokota T., Saito Y., and Miyatake T. Conduction slowing without conduction block of compound muscle and nerve action potentials due to sodium channel block. J Neurol Sci 124 (1994) 220-224
92. Stys P.K., Ransom B.R., and Waxman S.G. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J Neurophysiol 67 (1992) 236-240
93. Brinkmeier H., Wollinsky K.H., Hulser P.J., et al. The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid. Pflugers Arch 421 (1992) 552-557
94. Wurz A., Brinkmeier H., Wollinsky K.H., et al. Cerebrospinal fluid and serum from patients with inflammatory polyradiculoneuropathy have opposite effects on sodium channels. Muscle Nerve 18 (1995) 772-781
95. Corbo M., Quattrini A., Latov N., et al. Localization of GM1 and Gal(beta 1-3)GalNAc antigenic determinants in peripheral nerve. Neurology 43 (1993) 809-814
96. Kuwabara S., Yuki N., Koga M., et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 44 (1998) 202-208
97. Yuki N., Yamada M., Koga M., et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49 (2001) 712-720
98. Susuki K., Rasband M.N., Tohyama K., et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27 (2007) 3956-3967
99. Kiernan M.C., Burke D., Andersen K.V., et al. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 23 (2000) 399-409
100. Kiernan M.C., Hart I.K., and Bostock H. Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 70 (2001) 56-64
101. Kuwabara S., Ogawara K., Sung J.Y., et al. Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. Ann Neurol 52 (2002) 180-187
102. Triggs W.J., Cros D., Gominak S.C., et al. Motor nerve inexcitability in Guillain-Barré syndrome. The spectrum of distal conduction block and axonal degeneration. Brain 115 (1992) 1291-1302
103. Hirota N., Kaji R., Bostock H., et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 120 (1997) 2159-2169
104. Dilley A., Gregson N.A., Hadden R.D., et al. Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barré syndrome. J Neuroimmunol 139 (2003) 133-140
105. Hartung H.P., Reiners K., Schmidt B., et al. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 30 (1991) 48-53
106. Brinkmeier H., Kaspar A., Wietholter H., et al. Interleukin-2 inhibits sodium currents in human muscle cells. Pflugers Arch 420 (1992) 621-623
107. Barontini F., Di Lollo S., Maurri S., et al. Localization of the pathological process in Miller Fisher syndrome. Ital J Neurol Sci 13 (1992) 221-225
108. Phillips M.S., Stewart S., and Anderson J.R. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 47 (1984) 492-495
109. Berlit P., and Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol 12 (1992) 57-63
110. Al-Din A.N., Anderson M., Bickerstaff E.R., et al. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain 105 Pt 3 (1982) 481-495
111. Ropper A. Abscence of CNS lesion in autopsied patients with Miller-Fisher syndrome. Arch Neurol 42 (1985) 15
112. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 35 (2007) 691-711
113. Jacobs B.C., Endtz H., van der Meche F.G., et al. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 37 (1995) 260-264
114. Jacobs B.C., Hazenberg M.P., van Doorn P.A., et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 175 (1997) 729-733
115. Jacobs B.C., Endtz H.P., van der Meche F.G., et al. Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome. J Neuroimmunol. 79 (1997) 62-68
116. Ohtsuka K., Nakamura Y., Hashimoto M., et al. Fisher syndrome associated with IgG anti-GQ1b antibody following infection by a specific serotype of Campylobacter jejuni. Ophthalmology 105 (1998) 1281-1285
117. Chiba A., Kusunoki S., Obata H., et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 745 (1997) 32-36
118. Panda S., and Tripathi M. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 72 (2002) 418-419
119. Suzuki T., Chiba A., Kusunoki S., et al. Anti-GQ1b ganglioside antibody and ophthalmoplegia of undetermined cause. Br J Ophthalmol 82 (1998) 916-918
120. Kusunoki S., Chiba A., and Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 22 (1999) 1071-1074
121. Bullens R.W., Halstead S.K., O'Hanlon G.M., et al. Concanavalin A inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse. Muscle Nerve 31 (2005) 751-760
122. O'Hanlon G.M., Plomp J.J., Chakrabarti M., et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124 (2001) 893-906
123. Buchwald B., Bufler J., Carpo M., et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 56 (2001) 67-74
124. Buchwald B., Weishaupt A., Toyka K.V., et al. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 10 (1998) 281-290
125. Susuki K., Baba H., Tohyama K., et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 55 (2007) 746-757
126. Bersano A., Carpo M., Allaria S., et al. Long term disability and social status change after Guillain-Barré syndrome. J Neurol 253 (2006) 214-218
127. Bernsen R.A., de Jager A.E., Schmitz P.I., et al. Long-term impact on work and private life after Guillain-Barré syndrome. J Neurol Sci 201 (2002) 13-17
128. Chio A., Cocito D., Leone M., et al. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60 (2003) 1146-1150
129. Visser L.H., Schmitz P.I., Meulstee J., et al. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 53 (1999) 598-604
130. Petzold A., Hinds N., Murray N.M., et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology 67 (2006) 1071-1073
131. Hughes R.A., Wijdicks E.F., Benson E., et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 62 (2005) 1194-1198
132. Meythaler J.M. Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil 78 (1997) 872-879
133. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-104.
134. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298-306.
135. Greenwood R.J., Newsom-Davis J., Hughes R.A., et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1 (1984) 877-879
136. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-761.
137. McKhann G.M., Griffin J.W., Cornblath D.R., et al. Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome. J Neuroimmunol 20 (1988) 297-300
138. Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Intensive Care Med 2000;26:1094-1100.
139. Vucic S., and Davies L. Safety of plasmapheresis in the treatment of neurological disease. Aust N Z J Med 28 (1998) 301-305
140. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123-1129.
141. Bril V., Ilse W.K., Pearce R., et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46 (1996) 100-103
142. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange intravenous immunoglobulin and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
143. Diener H.C., Haupt W.F., Kloss T.M., et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 46 (2001) 107-109
144. Nomura T., Hamaguchi K., Hattori T., et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol Therapeutics 18 (2000) 69-81
145. Korinthenberg R., Schessl J., Kirschner J., et al. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 116 (2005) 8-14
146. Haupt W.F., Rosenow F., van der Ven C., et al. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 137 (1996) 145-149
147. Hughes R.A., Wijdicks E.F., Barohn R., et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 736-740
148. Raphael JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002:CD001798.
149. Farcas P, Avnun L, Frisher S, et al. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997;350:1747.
150. Hughes R.A., Swan A.V., Raphael J.C., et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130 (2007) 2245-2257
151. Bansal B., Sood A.K., Gupta A.K., et al. Role of steroids in the treatment of Guillain-Barré syndrome - a controlled trial. Neurol India 34 (2004) 329-335
152. Hughes R.A., Newsom-Davis J.M., Perkin G.D., et al. Controlled trial prednisolone in acute polyneuropathy. Lancet 2 (1978) 750-753
153. Shukla S., Agarwal R., Gupta O.P., et al. Double blind control trial of prednisolone in Guillain-Barré syndrome - a clinical study. Clinician India 52 (1988) 128-134
154. Singh N.K., and Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome?. J Assoc Physicians India 44 (1996) 22-24
155. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590.
156. van Koningsveld R., Schmitz P.I., Meche F.G., et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363 (2004) 192-196
157. Hughes R.A., Swan A.V., Raphael J.C., et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130 (2007) 2245-2257
158. Garssen M.P., Van Koningsveld R., and Van Doorn P.A. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome. J Neurol 253 (2006) 1143-1146
159. Andersen S.M., Ling C.C., Zhang P., et al. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome. Org Biomol Chem 2 (2004) 1199-1212
160. Stys P.K. General mechanisms of axonal damage and its prevention. J Neurol Sci 233 (2005) 3-13
161. Halstead S.K., Zitman F.M., Humphreys P.D., et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131 (2008) 1197-1208
162. Halstead S.K., Humphreys P.D., Goodfellow J.A., et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 58 (2005) 203-210
163. Putzu G.A., Figarella-Branger D., Bouvier-Labit C., et al. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barré syndrome. J Neurol Sci 174 (2000) 16-21